The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Under normal physiological conditions, the kynurenine pathway (KP) plays a critical role in generating cellular energy and catabolizing tryptophan. Under inflammatory conditions, however, there is an upregulation of the KP enzymes, particularly kynurenine 3-monooxygenase (KMO). KMO has garnered much attention due to its production of toxic metabolites that have been implicated in many diseases and disorders. With many of these illnesses having an inadequate or modest treatment, there exists a need to develop KMO inhibitors that reduce the production of these toxic metabolites. Though prior efforts to find an appropriate KMO inhibitor were unpromising, the development of a KMO crystal structure has provided the opportunity for a rational structure-based design in the development of inhibitors. Therefore, the purpose of this review is to describe the kynurenine pathway, the kynurenine 3-monooxygenase enzyme, and KMO inhibitors and their potential candidacy for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“Until now, pharmacologic treatments for AD have tried to control cognitive deficits through the administration of acetylcholinesterase inhibitors in an effort to increase acetylcholine levels in the CNS, but such strategies have only had modest success [80].”
BackgroundQuinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595 · cited 1×
“QUIN compromises the integrity of the blood–brain barrier (BBB), generates reactive oxygen intermediates, and depletes endogenous antioxidants and peroxidation of lipid molecules [51].”
BackgroundIncreased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Uher, R., Payne, J. L., Pavlova, B., & Perlis, R. H. (2014) · Depression and Anxiety · doi:10.1002/da.22217 · Cited by 456 · cited 1×
“Depression, also referred to as clinical depression or major depressive disorder (MDD) [93,94], is a multifactorial mood disorder that is characterized by anhedonia [95].”
BackgroundLugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverrí, J., Silva-Adaya, D., Maldonado, P. D., Torres, I., Pinzón, E., Ortiz-Islas, E., et al. (2011) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2011.07.002 · Cited by 346
The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
Rahman, A., Ting, K., Cullen, K. M., Braidy, N., Brew, B. J., & Guillemin, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006344 · Cited by 257
Differential vulnerability of central neurons of the rat to quinolinic acid
Schwarcz, R., & Köhler, C. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90115-5 · Cited by 239
Yamada, A., Akimoto, H., Kagawa, S., Guillemin, G. J., & Takikawa, O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06175.x · Cited by 58
Kynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders
Fila, M., Chojnacki, J., Pawlowska, E., Szczepanska, J., Chojnacki, C., & Blasiak, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810134 · Cited by 50 · cited 2×
“When metabolized by the serotonin (5-hydroxyptamine, 5-HT) pathway, 5-hydroxytryptamine or serotonin, a key hormone, affects mood, sleep, and pain [1].”
Background
Cited by
Huang, Y., Zhao, M., Chen, X., Zhang, R., Le, A., Hong, M., Zhang, Y., Jia, L., Zang, W., Jiang, C., et al. (2023) · Aging and disease · doi:10.14336/ad.2022.0916 · Cited by 138
“Ro 61-8048 Neurodegenerative or neurologic disorders/Preclinical [196] Competitive inhibitor [197]; Poor penetration of BBB in rats [195].”
BackgroundPuopolo, T., Chang, T., Liu, C., Li, H., Liu, X., Wu, X., Ma, H., & Seeram, N. P. (2022) · Biology · doi:10.3390/biology11101416 · Cited by 13
Ibos, K. E., Bodnár, É., Dinh, H., Kis, M., Márványkövi, F., Kovács, Z. Z. A., Siska, A., Földesi, I., Galla, Z., Monostori, P., et al. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-023-02884-y · Cited by 8
Metadata
- Authors
- Hughes, T. D., Güner, O. F., Iradukunda, E. C., Phillips, R. S., & Bowen, J. P.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-01-02
- Volume
- 27
- Issue
- 1
- Pages
- 273
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W4205213916
- Cited by
- 83
- References
- 10
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors. https://app.cochat.ai/papers/10.3390/molecules27010273
- The paper
- Hughes, T. D., Güner, O. F., Iradukunda, E. C., Phillips, R. S., & Bowen, J. P. (2022). The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors. Molecules. https://doi.org/10.3390/molecules27010273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.